Enabling Personalized Medicine
Our patented technology simultaneously analyzes multiple biomarkers in tumors in order to predict patient response to one or more targeted therapies. As the number of therapies that target signaling pathways increase, it is expected that this technology will ensure that cancer patients will receive the most appropriate therapies and improve survival. |
|
Early Detection of Cancer
Our simple blood test detects cancer biomarkers at the earliest stages of tumor development, before symptoms become apparent and where treatments have the greatest chance of success. Our portfolio of proprietary and licensed biomarkers is being combined into a new test focused primarily at high risk patients for Lung cancer and Head & Neck cancer. |
